TNFRSF17 (BCMA, CD269) is a TNF receptor family member expressed almost exclusively on plasma cells, transmitting BAFF/APRIL survival signals. BCMA is the leading clinically validated target for multiple myeloma CAR-T therapy.
| Catalog No. | Product Name | Conjugate | Size | Price (In USD) |
|---|---|---|---|---|
| GM-Tg-hg-T66693-Ab-3-PE | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(PE) | PE | 25T | |
| GM-Tg-hg-T66693-Ab-3-PE | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(PE) | PE | 100T | |
| GM-Tg-hg-T66693-Ab-3-PE | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(PE) | PE | 500T | |
| GM-Tg-hg-T66693-Ab-3-FITC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(FITC) | FITC | 25T | |
| GM-Tg-hg-T66693-Ab-3-FITC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(FITC) | FITC | 100T | |
| GM-Tg-hg-T66693-Ab-3-FITC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(FITC) | FITC | 500T | |
| GM-Tg-hg-T66693-Ab-3-APC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(APC) | APC | 25T | |
| GM-Tg-hg-T66693-Ab-3-APC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(APC) | APC | 100T | |
| GM-Tg-hg-T66693-Ab-3-APC | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(APC) | APC | 500T | |
| GM-Tg-hg-T66693-Ab-3-Biotin | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(Biotin) | Biotin | 25T, 100T, 500T |
| Target | BCMA (specific biomarker for human plasma cell) |
|---|---|
| Species | Humanized |
| Expression platform | Mammalian cell |
| Isotypes | Human IgG |
| Tag | hFc |
| Conjugate | PE / FITC / APC / Biotin |
| Size | 25T / 100T / 500T |
| Purity | >=95% (SDS-PAGE) |
| Bioactivity validation | BCMA binding, FACS in BCMA level test |
| Application | FACS and other Immunoassay for BCMA test |
| Products description | Anti-Human TNFRSF17/BCMA/CD269 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) is a recombinant monoclonal antibody. It specifically recognizes BCMA (TNF receptor superfamily member 17, highly restricted to plasma cells). BCMA is a plasma cell marker. This antibody is validated by FACS for multiple-myeloma target assessment for BCMA CAR-T. It is recommended for multi-color flow cytometry panels to validate BCMA expression on patient plasma cells for BCMA CAR-T screening in CAR-T cell therapy manufacturing, QC and functional assessment. |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |